From the publishers of JADPRO

Metastatic Triple-Negative Breast Cancer Resource Center

Advertisement

Drug discovery today

Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options

Journal of Clinical Medicine

Current therapeutic strategies for metastatic triple-negative breast cancer: From pharmacists’ perspective

ASCO 2023, Journal of Clinical Oncology

The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction

Oncologist

Incidence and resolution of eribulin-induced peripheral neuropathy (IRENE) in locally advanced or metastatic breast cancer: Prospective cohort study

European Journal of Cancer

Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort

Breast Cancer Research and Treatment

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer

Critical Reviews in Oncology/Hematology

Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey

Breast Cancer: Basic and Clinical Research

Implementation of risk-stratified breast cancer prevention with a polygenic risk score test in clinical practice

The ASCO Post

Current management of and future possibilities for triple negative breast cancer

Breast Cancer: Basic and Clinical Research

Real-world survival and treatment regimens across first- to third-line treatment for advanced triple-negative breast cancer

Therapeutic Advances in Medical Oncology

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: First observations from an interdisciplinary breast cancer centre in Germany

Expert Review of Anticancer Therapy

The role of immune checkpoint inhibition in triple negative breast cancer

Cancers

Role of cardiac biomarkers in cancer patients

JAMA Network Open

Risk prediction models for cardiotoxicity of chemotherapy among patients with breast cancer: A systematic review

The New England Journal of Medicine

Update on Triple-Negative Breast Cancer Disparities for the United States: A Population-Based Study From the United States Cancer Statistics Database, 2010 Through 2014

Frontiers in Oncology

Long-term cardiac safety and survival outcomes of neoadjuvant pegylated liposomal doxorubicin in elderly patients or prone to cardiotoxicity and triple negative breast cancer. Final results of the multicentre phase II CAPRICE study

Frontiers in Cardiovascular Medicine

Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery

JACC Cardio Oncology

Cardio protection in patients at high risk of anthracycline induced cardiotoxicity

JAMA Network Open

Risk Prediction Models for cardiotoxicity of chemotherapy among patient with breast cancer

ASCO 2023, Journal of Clinical Oncology

Older patients with early-stage triple-negative breast cancer: The Memorial Sloan Kettering Cancer Center experience

ASCO 2023, Journal of Clinical Oncology

Pharmacological cardioprotective strategy for non-metastatic patients affected by breast cancer receiving an anthracycline-based chemotherapy: Final results of the phase 3 SAFE trial

ASCO 2023, Journal of Clinical Oncology

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies

National Comprehensive Cancer Network

NCCN releases statement addressing ongoing chemotherapy shortages; shares survey results finding more than 90% of cancer centers are impacted

Biomarker Insights

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker

Breast Cancer Research and Treatment

Immunotherapy Toxicity: Identification and Management

Drug Discovery Today

Triple-Negative Breast Cancer Brain Metastasis: An Update on Druggable Targets, Current Clinical Trials, and Future Treatment Options

Annals of Translational Medicine

Severe Immune-Related Hepatitis and Myocarditis Caused by PD-1 Inhibitors in the Treatment of Triple-Negative Breast Cancer: A Case Report

The ASCO Post

ASCO Updated Guideline of Biomarkers in Metastatic Breast Cancer Supports PIK3CA, BRCA1/2, PD-L1 Testing

Expert Opinion on Biological Therapy

Harmonizing PD-L1 Testing in Metastatic Triple Negative Breast Cancer

Cancer Reports

Ethnic Disparities in the Immune Microenvironment of Triple Negative Breast Cancer and Its Role in Therapeutic Outcomes

Future Medicine

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Case Reports in Oncology

Neutropenic Enterocolitis: A Rare Complication of Sacituzumab Govitecan

Cancer Treatment Reviews

Optimizing Choices and Sequences in the Diagnostic-Therapeutic Landscape of Advanced Triple-Negative Breast Cancer: An Italian Consensus Paper and Critical Review

European Journal of Cancer

Health-Related Quality of Life in the Phase III ASCENT Trial of Sacituzumab Govitecan Versus Standard Chemotherapy in Metastatic Triple-Negative Breast Cancer

Clinical Advances in Hematology & Oncology

Managing Adverse Events of Immunotherapy in Breast Cancer

Cell Research

Molecular Subtyping and Genomic Profiling Expand Precision Medicine in Refractory Metastatic Triple-Negative Breast Cancer: The FUTURE Trial

ESMO Open

Influence of HER2 Expression on Prognosis in Metastatic Triple-Negative Breast Cancer—Results From an International, Multicenter Analysis Coordinated by the AGMT Study Group

JCO Precision Oncology

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit

Epidemiology

Are There Differences in Outcomes by Race Among Women With Metastatic Triple-Negative Breast Cancer?

Current Oncology

Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer

JAMA Oncology

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors

NPJ Breast Cancer

Immunotherapy in Triple Negative Breast Cancer: Beyond Checkpoint Inhibitors

Expert Opinion on Investigational Drugs

Progress and Pitfalls in the Use of Immunotherapy for Patients With Triple Negative Breast Cancer

Frontiers in Public Health

Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices

Therapeutic Advances in Medical Oncology

Emerging Treatment Strategies for Metastatic Triple-Negative Breast Cancer

Expert Review of Anticancer Therapy

Atezolizumab and Pembrolizumab in Triple-Negative Breast Cancer: A Meta-Analysis

JCO Precision Oncology

Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer

ESMO Congress 2022

Primary Endpoint Results of SYNERGY, a Randomized Phase II Trial, First-Line Chemo-Immunotherapy Trial of Durvalumab, Paclitaxel, and Carboplatin With or Without the Anti-CD73 Antibody Oleclumab

Cancer Discovery

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple Negative Breast Cancer

Journal of Clinical Oncology

Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer

ESMO Congress 2022

Primary Endpoint Analysis of a Randomized Phase II Trial of Darolutamide or Capecitabine in Patients With Triple-Negative Androgen Receptor-Positive Advanced Breast Cancer (UCBG3-06 START Trial)

ESMO Congress 2022

Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line Treatment for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer: Initial Results From BEGONIA, a Phase 1b/2 Study

PharmacoEconomics

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

Nature Reviews Clinical Oncology

Treatment Landscape of Triple-Negative Breast Cancer—Expanded Options, Evolving Needs

Medicine

Case Report of Long-Term Survival With Metastatic Triple-Negative Breast Carcinoma: Treatment Possibilities for Metastatic Disease

Physiological Reports

Diet Impacts Triple-Negative Breast Cancer Growth, Metastatic Potential, Chemotherapy Responsiveness, and Doxorubicin-Mediated Cardiac Dysfunction

Future Oncology

Real-World Effectiveness Outcomes in Patients Diagnosed With Metastatic Triple-Negative Breast Cancer

Science Translational Medicine

Genomic and Epigenomic BRCA Alterations Predict Adaptive Resistance and Response to Platinum-Based Therapy in Patients With Triple-Negative Breast and Ovarian Carcinomas

The Oncologist

Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities

NPJ Precision Oncology

A DNA Methylation-Based Liquid Biopsy for Triple-Negative Breast Cancer

Expert Opinion on Investigational Drugs

Immune-Based Combinations for Metastatic Triple Negative Breast Cancer in Clinical Trials: Current Knowledge and Therapeutic Prospects

New England Journal of Medicine

Pembrolizumab Plus Chemotherapy in Advanced Triple-Negative Breast Cancer

The ASCO Post

Study Examines Ancestry-Specific Genetic Risk for Triple-Negative Breast Cancer

2022 ASCO Annual Meeting

The Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab in Patients With Locally Recurrent or Metastatic Triple-Negative Breast Cancer

2022 ASCO Annual Meeting

Apatinib Plus Etoposide as Second- or Higher-Line Treatment in Recurrent or Metastatic Triple-Negative Breast Cancer: A Single-Arm, Open Label, Prospective, Phase II Clinical Trial

2022 ASCO Annual Meeting

Treatment Advances in Metastatic Triple-Negative Breast Cancer (TNBC): Addressing the Knowledge Gap

2022 ASCO Annual Meeting

Real-World Data Comparing Third and Subsequent Line Regimens for Treatment of Metastatic Triple-Negative Breast Cancer in the United States

Epidemiology

Outcome of Patients With Metastatic Triple Negative Breast Cancer Treated With First-Line Chemotherapy: A Single Institution Retrospective Analysis

JNCCN

Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer

Cancer and Metastasis Review

Checkpoint Inhibitor Therapy for Metastatic Triple-Negative Breast Cancer

World Journal of Clinical Oncology

Overview of Recent Advances in Metastatic Triple Negative Breast Cancer

International Journal of Molecular Sciences

Multi-Gene Testing Overview With a Clinical Perspective in Metastatic Triple-Negative Breast Cancer

Journal of Oncology Pharmacy Practice

Case Report of Sacituzumab Govitecan-hziy-Induced Neutropenia in a Patient With Metastatic Triple-Negative Breast Cancer and a Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 Poor Metabolizer Genotype

Scientific Reports

Addition of Immune Checkpoint Inhibitors to Chemotherapy Versus Chemotherapy Alone in First-Line Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis

Nature Reviews Clinical Oncology

Immune-Checkpoint Inhibition for Metastatic Triple-Negative Breast Cancer: Safety First?

ESMO Open

How I Treat Metastatic Triple-Negative Breast Cancer

Breast Cancer: Targets and Therapy

Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective

New England Journal of Medicine

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Asia-Pacific Journal of Clinical Oncology

Metastatic Triple Negative Breast Cancer: Optimizing Treatment Options, New and Emerging Targeted Therapies

The ASCO Post

KEYNOTE-355 Final Analysis Reveals Survival Benefit With Pembrolizumab in Triple-Negative Breast Cancer

2021 San Antonio Breast Cancer Symposium

Datopotamab Deruxtecan in Advanced/Metastatic HER2- Breast Cancer: Results From the Phase 1 TROPION-Pantumor01 Study

Pharmaceuticals

Immunotherapy Treatment for Triple Negative Breast Cancer

Patient With Lung Metastasis and HER2-Low Status: Evolving Treatment Options

Treatment of a Patient With AML and mTNBC

Fast Facts #6: Immunotherapy and Endocrinopathies